Durham, NC -- (ReleaseWire) -- 11/10/2015 -- Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been accepted to present at the 1776 Challenge Cup Local, being held November 11, 2015 at the American Underground @Main in Durham, North Carolina.

"In the United States alone, 4 million people wear braces and most of them agree that braces are painful," said Christopher Meldrum, President & CEO of Arcato Laboratories. "Arcato's solution is OraWax™, a patented time-release formulation combining wax, benzocaine, and special polymers," he added.

Each year, 1776, a global incubator and venture fund, hosts a worldwide tournament called the Challenge Cup. Together, with its Startup Federation partners and over 50 incubator hosts around the world, it discovers the most promising, highly scalable startups that are poised to solve the major challenges of our time.

Startups advance through three rounds: Local, Regional, and Global Finals. All of the regional winners and a host of wild cards will be invited to participate in the Challenge Cup Global Finals next June in Washington, D.C. There, they will compete for over $1 million in prizes, as well as spend time with the investors, customers, media and other key connections that can help them succeed on a global scale.

Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.

About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato's first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.

Contact Christopher S. Meldrum: cmeldrum@arcatolabs.com
Company website: http://www.arcatolabs.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

To date, over 365 biotech companies have raised more than $2.5 billion in public and private funding at previous SEBIO forums. Arcato Laboratories, developer of OraWaxTM, has been selected to present at the Southeast BIO Investor & Partnering Forum (SEBIO) November 11-13.

Durham, NC -- (ReleaseWire) -- 10/27/2015 -- Arcato Laboratories, developer of OraWaxTM, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to present at the Southeast BIO Investor & Partnering Forum (SEBIO), being held November 11-13, 2015 at the Belmond Charleston Place in Charleston, South Carolina. The presentation will be delivered by Christopher S. Meldrum, President & CEO of Arcato Laboratories.

"The technology platform of Arcato Laboratories is based upon a patented method of delivering a local anesthetic to oral mucosal membranes over a sustained period of time," said Meldrum. "The Arcato technology platform has many applications for other types of pain relief, but the OraWax™ product alone has an estimated market of about $400 million per year," he added.

Celebrating its 17th year, the SEBIO Investor & Partnering Forum has built a loyal following, attracting thought leaders and investors from across the country. To date, the more than 200 later stage and 165 early stage companies that participated in previous SEBIO Investor & Partnering Forums have raised more than $2.5 billion in public and private funding.

Arcato is currently raising $1 million in a Series B round of financing, to complete 510(k) FDA regulatory clearance for OraWax™, and launch the product in the United States.

About Arcato Laboratories
Arcato Laboratories, a leader in the sustained release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato's first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces).

For more information on investing, please visit our Investor Relations Page.

Contact Christopher S. Meldrum: cmeldrum@arcatolabs.com
Company website: http://www.arcatolabs.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Arcato Laboratories Chief Executive Officer Interviewed About OraWaxTM on The Private Capital News Network. During a three-minute video news story, Meldrum described where the company was along the path of commercializing its first product, OraWax™.

Durham, NC -- (ReleaseWire) -- 08/06/2015 -- Christopher S. Meldrum, Chief Executive Officer of Arcato Laboratories, was featured in a three-minute video news story, produced by The Private Capital News Network. Meldrum described where the company was along the path of commercializing its first product, OraWax™.

"Right now," said Meldrum, "there is no treatment for orthodontic brace pain." Meldrum described how the patented technology behind OraWax™ allows for a slow, sustained release of benzocaine that provides longterm relief from the discomfort associated with wearing braces.

Meldrum explained that Arcato Labs was entering the final stages of obtaining regulatory approval for the OraWax™ product, with an anticipated market launch within 12 months. "We are raising capital to complete the process of regulatory clearance, and will launch the product in the United States using a regional-focused roll out," he said.

The video news story is available on the Arcato Labs investors relations website, where potential investors may obtain information about the company and the security offering.

Arcato is currently raising a Series B round of financing, to commercialize OraWax™ and fund research on its patented technology.

About Arcato Laboratories
Arcato Laboratories, a leader in the sustained-release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato's first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces). For more information on investing, please visit our Investor Relations Page.

Contact Christopher S. Meldrum: cmeldrum@arcatolabs.com
Company website: http://www.arcatolabs.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Durham, NC -- (ReleaseWire) -- 07/28/2015 -- Arcato Laboratories, developer of OraWax, a revolutionary new treatment for the discomfort caused by orthodontic braces, has been selected to present at the North Carolina Triangle TechBreakfast on July 23, 2015.

The event is a monthly breakfast get-together of North Carolina technology companies, software developers and designers, and entrepreneurs to learn about technology commercialization projects in central North Carolina. It is free to the public and will take place at 8:00 a.m. at the RTP Headquarters, located at 12 Davis Drive, Research Triangle Park, situated between Raleigh and Durham, North Carolina.

The research related to the OraWax patent was undertaken by Dr. Michael Jay, the founder of Arcato and its CSO. Dr. Jay is also the Fred Eshelman Distinguished Professor of molecular pharmaceutics at the University of North Carolina at Chapel Hill, and is an expert on drug delivery and drug formulations.

The presentation will be delivered by Christopher S. Meldrum, CEO of Arcato Laboratories.

"In the United States alone, 4 million people wear braces and most of them agree that braces are painful," said Meldrum. "Arcato's solution is OraWax™, a patented time-release formulation combining wax, benzocaine, and special polymers," he added.

Arcato is currently raising money to complete FDA regulatory clearance for OraWax™. The company is issuing its Series B Convertible Participating Preferred Stock, which is in turn convertible into shares of the Company's common stock.

"Arcato is issuing securities directly to investors in the new Reg D 506 (c) offering," said Thomas Vass, the investment advisor to the company. "The common term for this type of offering is equity crowdfunding, and we are proud to be one of the first technology companies in North Carolina to undertake this type of internet-based offering," he added.

About Arcato Laboratories
Arcato Laboratories, a leader in the sustained-release of anesthetics, is commercializing proprietary products to serve specialty oral healthcare practitioners, such as orthodontists and oral surgeons. Arcato's first product, a medical device named OraWax™, targets orthodontists and their patients as the first effective treatment for oral discomfort caused by orthodontic appliances (braces).

For more information on investing, please visit our Investor Relations Page.

Contact Christopher S. Meldrum: cmeldrum@arcatolabs.com
Company website: http://www.arcatolabs.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm